Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

The maker of Slim Jims and Healthy Choice frozen meals posted a profit of $145.1 million, or 30 cents a share, for the quarter ended Feb. 23. That's down from $308.6 million, or 64 cents a share, in ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.

Telehealth firms have been partnering with LillyDirect to offer Lilly's weight-loss drug, Zepbound. These companies have been on the lookout for an avenue to sell highly popular weight-loss drugs, as ...

Hims & Hers is now offering Zepbound and generic ... expects $725M from weight-loss sales in 2025 WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is ...